Division of Cardiac Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Curr Opin Organ Transplant. 2022 Jun 1;27(3):222-228. doi: 10.1097/MOT.0000000000000982.
Since the first implantation of a total artificial heart (TAH) 50 years ago the devices and technique have evolved to provide reliable support for patients with biventricular failure as a bridge to heart transplant. The purpose of this review is to discuss the history and evolution of devices, current devices, critical aspects of patient selection, tips and pitfalls of implantation, and future directions.
The most studied device on the market is the SynCardia TAH, which has been implanted in over 2000 patients worldwide and is the only device that is currently Food and Drug Administration approved as a bridge to transplant. The overall survival in patients supported by the device at 1 year is 42% while those that make it to transplant have a 1 year post transplant survival of 83%. A newer device the Aeson TAH (Carmat, Velizy-Villacoublay, France) was first implanted in France in 2013 and is currently under clinical trial in the United States.
Significant progress has been made in both the technology and technique of TAH implantation and these devices remain both a reliable and sometimes only option for patients with severe biventricular heart failure.
自 50 年前首例全人工心脏（TAH）植入以来，这些设备和技术不断发展，为双心室衰竭患者提供了可靠的支持，作为心脏移植的桥梁。本文的目的是讨论设备的历史和演变、当前的设备、患者选择的关键方面、植入的技巧和窍门以及未来的方向。
目前市场上研究最多的设备是 SynCardia TAH，该设备已在全球超过 2000 名患者中植入，是唯一一款获得美国食品和药物管理局批准作为移植桥的设备。该设备支持的患者在 1 年时的总生存率为 42%，而那些成功进行移植的患者在移植后 1 年的生存率为 83%。一种新型设备 Aeson TAH（Carmat，法国 Velizy-Villacoublay）于 2013 年在法国首次植入，目前正在美国进行临床试验。
在 TAH 植入的技术和技术方面都取得了重大进展，这些设备仍然是严重双心室心力衰竭患者的可靠且有时唯一的选择。
